Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.

@article{Carro2006TherapeuticAO,
  title={Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.},
  author={Eva Carro and Jos{\'e} Luis Trejo and Alexandra Lehmkuhl Gerber and Hansruedi Loetscher and Julio Torrado and Friedrich Metzger and Ign{\'a}cio Torres-Aleman},
  journal={Neurobiology of aging},
  year={2006},
  volume={27 9},
  pages={1250-7}
}
Transgenic mice expressing mutant forms of both amyloid-beta (Abeta) precursor protein (APP) and presenilin (PS) 2 develop severe brain amyloidosis and cognitive deficits, two pathological hallmarks of Alzheimer's disease (AD). One-year-old APP/PS2 mice with high brain levels of Abeta and abundant Abeta plaques show disturbances in spatial learning and memory. Treatment of these deteriorated mice with a systemic slow-release formulation of insulin-like growth factor I (IGF-I) significantly… CONTINUE READING